RECRUITINGINTERVENTIONAL

rTMS as an Intervention for Levodopa-induced Dyskinesia

Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)

About This Trial

The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.

Who May Be Eligible (Plain English)

Who May Qualify: - Clinically established or probable PD - Clinical Diagnostic Criteria for Parkinson's Disease - Peak-of-dose levodopa-induced dyskinesia. - Stable antiparkinsonian medicine for at least four weeks. - Signed willing to sign a consent form. Who Should NOT Join This Trial: - Psychiatric disorders. - Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). - Regular usage of benzodiazepines and opioids (more than once per week). - History of neurological disease other than Parkinson's disease. - History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. - Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. - Contraindications for MRI scan - Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. - Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Clinically established or probable PD * Clinical Diagnostic Criteria for Parkinson's Disease * Peak-of-dose levodopa-induced dyskinesia. * Stable antiparkinsonian medicine for at least four weeks. * Signed informed consent. Exclusion Criteria: * Psychiatric disorders. * Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). * Regular usage of benzodiazepines and opioids (more than once per week). * History of neurological disease other than Parkinson's disease. * History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Contraindications for MRI scan * Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. * Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.

Treatments Being Tested

DEVICE

active TMS

Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil

DEVICE

sham TMS

Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil

Locations (1)

DRCMR

Hvidovre, Denmark